|
Video: What is a Stock Split?
|
|
Ayala Pharmaceuticals is a clinical stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. Co.'s portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway using gamma secretase inhibitors. Gamma secretase is the enzyme responsible for Notch activation and, when inhibited, turns off the Notch pathway activation. Aberrant activation of the Notch pathway has long been implicated in various solid tumor and hematological cancers and has often been associated with more aggressive cancers. According to our Ayala Pharmaceuticals stock split history records, Ayala Pharmaceuticals has had 0 splits. | |
|
Ayala Pharmaceuticals (AYLA) has 0 splits in our Ayala Pharmaceuticals stock split history database.
Looking at the Ayala Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Ayala Pharmaceuticals shares, starting with a $10,000 purchase of AYLA, presented on a split-history-adjusted basis factoring in the complete Ayala Pharmaceuticals stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
05/11/2020 |
|
End date: |
01/19/2023 |
|
Start price/share: |
$15.15 |
|
End price/share: |
$0.50 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-96.67% |
|
Average Annual Total Return: |
-71.74% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$332.60 |
|
Years: |
2.69 |
|
|
|
|
|